Prospera Financial Services Inc Buys 17,702 Shares of Eli Lilly and Company $LLY

Prospera Financial Services Inc boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 64.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,963 shares of the company’s stock after acquiring an additional 17,702 shares during the quarter. Eli Lilly and Company accounts for approximately 0.7% of Prospera Financial Services Inc’s holdings, making the stock its 26th largest position. Prospera Financial Services Inc’s holdings in Eli Lilly and Company were worth $35,061,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of LLY. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $27,000. Blume Capital Management Inc. grew its position in Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares during the period. IMG Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at $35,000. Financial Gravity Asset Management Inc. bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at $40,000. Finally, TD Capital Management LLC boosted its stake in shares of Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Activity at Eli Lilly and Company

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CEO David A. Ricks purchased 1,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 4,314 shares of company stock worth $2,766,929 over the last 90 days. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Down 1.5%

NYSE LLY opened at $923.35 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $955.46. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market cap of $872.92 billion, a PE ratio of 60.35, a P/E/G ratio of 1.21 and a beta of 0.43. The stock’s 50 day moving average is $799.97 and its 200 day moving average is $775.76.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue was up 53.9% on a year-over-year basis. During the same period last year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 29.35%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on LLY. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday. The Goldman Sachs Group boosted their price target on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research note on Friday, October 10th. Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Finally, Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $960.88.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.